Patient selection for immunotherapy in gastric cancer
Monday, August 7, 2017
Manish A. Shah, M.D., joins an OncLive panel to discuss immunotherapy treatment for gastric cancer.
"The way to think of it is that we don’t know how to identify these patients who are going to respond. So if you are doing a clinical trial comparing a PD-1 inhibitor versus another active regimen, then you may need to enrich your population by some mechanism, like PD-L1 staining."